Day 2 articles

PC Trial: Clinical treatment or closure of patent foramen oval in cryptogenic stroke patients?

PC Trial: Clinical treatment or closure of patent foramen oval in cryptogenic stroke patients?

Background: The association between paradoxical embolism, including cryptogenic stroke, and the presence of patent foramen oval (PFO) has been found in previous clinical studies. However, the benefit of percutaneous PFO closure versus medical treatment is not clear, especially after the negative results of the randomized CLOSURE I trial. This study included patients with PFO and

POSEIDON study: A prospective, randomized, single-center study comparing a sliding-scale hydration strategy for the prevention of contrast-induced nephropathy.

Background: Contrast-induced nephropathy has been the subject of many studies not only because of the morbidity associated with prolonged hospital stay, (with dialysis requirement in some cases), but also with an increase in mortality in these patients. The preventive strategy hydration with saline solution 0.9% NaCl is the choice. However, the infusion rate and total

POST trial: Post-conditioning effect in myocardial reperfusion with primary angioplasty.

Ischemic postconditioning obtained through reversible ischemia and reproduced during reperfusion after a prolonged ischemic injury has shown comparable effects to ischemic preconditioning in preclinical phase. A study in humans showed a reduction in serum markers of AMI thanks to Ischemic postconditioning in the context of primary angioplasty. Different MRI studies showed conflicting results regarding the

RESPECT: Randomized clinical trial evaluated the patent foramen oval closure vs clinical treatment in patients with cryptogenic stroke

Fundamentals: Etiology of cryptogenic stroke stills a major challenge for medicine. Paradoxical embolism remains one of the possible causes. Undoubtedly, adults between 20 and 54 years represent a significant proportion of this population, and this is associated with a high morbidity and high costs not only in relation to the pathology itself but also to

AIDA STEMI MRI: Intracoronary versus intravenous abciximab in primary angioplasty. MRI analysis in AIDA study

Basics: Recent meta-analysis showed benefits of intracoronary abciximab administration compared with intravenous (A-EV). Although the AIDA study showed no such benefit when analyzing the combined endpoints of death, reinfarction and congestive heart failure, it did show a decrease of CHF in isolation over the group receiving intracoronary abciximab. This time, the study authors of AIDA

Top